Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...
Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback